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cardiovascular outcomes, and mortality (Liu et al., 2015). MGP acts as
a strong inhibitor of soft tissue calciﬁcation. As an illustration, MGP
knockout mice develop massive vascular calciﬁcation in their ﬁrst
weeks of life and die within 2 months of vessels' rupture (Luo et al.,
1997).
To acquire its full calciﬁcation inhibitory activity, MGP needs toMany lines of evidence have established that chronic kidney disease
and serine phosphorylation. Both modiﬁcations are not exerted
completely, so theoretically, four different MGP conformations can be(CKD) is associated with a substantially increased risk of cardiovascular
disease (CVD) (Epstein, 2015). In the majority of cases, the risk of CVD
exceeds the risk of progression to end-stage kidney disease. Conse-
quently, the “holy grail” of investigative interest is a search to elucidate
mechanisms that may promote and mediate this association and
potential interventions that may abrogate or attenuate CVD risk in CKD.
We and others have emphasized that although occlusive atheroscle-
rotic arterial disease undoubtedly occurs, the CVD associated with CKD
is characterized by arteriosclerosis, resulting in arterial stiffness that in
turn promotes structural heart disease (Epstein, 2015; Moody et al.,
2013). Aortic stiffening exposes the left ventricle to the ravages of
increased systolic pressures, leading to ventricular hypertrophy and
ﬁbrosis that may progress to cardiac failure.
Epidemiological studies have established that arterial stiffness
constitutes an important risk factor for cardiovascular events and
mortality in patients with CKD at all stages (Townsend, 2015). The
mechanisms that promote arterial stiffening in CKD are incompletely
deﬁned, and the optimal interventions for attenuating arterial stiffness
remain to be elucidated.
Among theproteins involved inmodulating vascular calciummetab-
olism, it has been hypothesized that the vitamin K-dependent matrix
Gla- (γ-carboxyglutamate) protein (MGP) plays a dominant role. MGP
is a local natural calciﬁcation inhibitor secreted primarily by
chondrocytes and vascular smooth muscle cells in the arterial tunica
media (Schurgers et al., 2010; Liu et al., 2015; Wei et al., 2016). MGP
requires vitamin K to be activated. Inactive MGP, known as
desphospho-uncarboxylated MGP (dp-ucMGP), can be measured inom.2016.01.011.
6960 (R-126), Miami, FL 33101,
. This is an open access article underundergo two post-translational modiﬁcations: glutamate carboxylation
found: unmodiﬁed and inactive as dp-ucMGP, only phosphorylated,
only carboxylated, and ﬁnally fully modiﬁed and active as phosphory-
lated and carboxylated MGP. In essence, high levels of plasma dp-
ucMGP are a proxy for vitamin K deﬁciency (Schurgers et al., 2010; Liu
et al., 2015; Wei et al., 2016).
Previous studies by the Leuven andMaastricht groups demonstrated
that in patients with diabetes (Liabeuf et al., 2014), renal dysfunction
(Schurgers et al., 2010), or macrovascular disease (Liu et al., 2015),
dp-ucMGP behaves as a circulating biomarker associated with cardio-
vascular risk, more severe vascular illness, and higher mortality. In the
recent Flemish Study on Environment, Genes and Health Outcomes
(FLEMENGHO), the investigators demonstrated that circulating dp-
ucMGP predicted total and cardiovascular mortality (Liu et al., 2015).
In contrast to dp-ucMGP, total uncarboxylated MGP (t-ucMGP) is not
a marker of vitamin K status, but rather reﬂects arterial calciﬁcation,
with lower values being associated with more widespread calcium
deposits. In accord with these formulations, vitamin K supplementation
has been shown to reduce aortic pulse wave velocity in healthy post-
menopausal women.
Whereas previous research on MGP has focused on macrovascular
complications, several lines of evidence suggest that renal microvascu-
lar traits including glomerular ﬁltration or microalbuminuria might
also be affected. As examples, MGP is abundantly expressed in the
kidney with MGP immunoreactivity being associated with the
epithelium of Bowman's capsule and the proximal tubules (Fraser and
Price, 1988). Furthermore mineral nanoparticles containing calcium
phosphate and calciﬁcation inhibitors are present in kidneys of patients
with end-stage renal disease, but not healthy controls, and probably
precede ectopic renal calciﬁcation (Wong et al., 2015). Moreover,
calciﬁcation of the arterial wall is the hallmark of renal impairment
and may involve arterioles with a diameter as small as 10 to 500 μm
(Lanzer et al., 2014). Consequently, the authors postulated that renalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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might be adversely affected by deﬁcient vitamin-K dependent
activation of MGP, as exempliﬁed by circulating dp-ucMGP.
In the present study published in this issue of EBioMedicine,Wei et al.
(2016) tested their hypothesis in white people enrolled in the
FLEMENGHO study and sought to replicate the ﬁndings in white and
black participants enrolled in the South African study regarding the
inﬂuence of sex, age and ethnicity on insulin sensitivity and cardiovas-
cular function (SAfrEIC). The authors demonstrated that among Flemish
and white and black Africans, for a doubling of dp-ucMGP, estimated
glomerular ﬁltration rate (eGFR) decreased by 1.5 (P = 0.023), 1.0
(P = 0.56), 2.8 (P = 0.0012) and 2.1 (P b 0.0001) mL/min/1.73 m2 in
Flemish, white Africans, black Africans and all participants combined.
The odds ratios for moving up one CKD stage were 1.17 (P = 0.033),
1.03 (P = 0.87), 1.29 (P = 0.12) and 1.17 (P = 0.011), respectively.
The authors interpreted their results by indicating that in the general
population, eGFR decreases and CKD risk increases with higher dp-
ucMGP, a marker of vitamin K deﬁciency. In summary, the authors
conﬁrmed the inverse association of eGFR with dp-ucMGP in black
South Africans and all South Africans combined.
The potential relevance of these observations is implicit. This study
emphasizes the nexus of vitamin K deﬁciency and CKD, and the
compelling need for attention to adequate vitamin K stores. These
epidemiological ﬁndings support the concept that active MGP might
not only inhibit calciﬁcation in large arteries, which was previously
documented (Knapen et al., 2015), but conceivably might also be
protective for renal function. Consequently the present observations
potentially highlight new therapeutic approaches for promoting renal
health, by increasing the dietary intake of vitamin K, either by supple-
mentation or by increasing the intake of nutrients rich in vitamin K. A
caveat is in order — as the authors emphasize, circulating levels of
vitamin K are rarely measured in clinical practice, because of the
complexity of the assay and because plasma levels only reﬂect dietary
intake over few hours without any indication of functionality, whereas
what really counts is the tissue level of active carboxylated MGP.
Therefore the focus should be on increasing the intake of nutrients
rich in vitamin K. Examples could include supplementation with
biologically enriched fermented vegetable or dairy products. Natural
food sources of vitamin K include vegetables such as spinach, asparagus,
broccoli, beans and soybeans, and eggs.In conclusion, the current ﬁndings by Wei et al. (2016) serve to
extend the protective role of vitamin K from the macrocirculation to
the microcirculation as exempliﬁed by renal function, and possibly
suggest a potential for prevention by vitamin K supplementation.
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